TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

LASTACAFT

ALCAFTADINE
Approved 2010-07-28
Jump to: Indications Approvals Trials Competitors Safety Patents
2
Indications
--
Phase 3 Trials
15
Years on Market

Details

Status
Over-the-counter
First Approved
2010-07-28
Routes
OPHTHALMIC
Dosage Forms
SOLUTION/DROPS

Companies

AbbVie
Active Ingredient: ALCAFTADINE

LASTACAFT Approval History

Loading approval history...

What LASTACAFT Treats

2 FDA approvals

Originally approved for its first indication in 2010 . Covers 2 distinct patient populations.

  • Other (2)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

LASTACAFT FDA Label Details

Pro

LASTACAFT Patents & Exclusivity

Latest Patent: Dec 2027

Patents (2 active)

US8664215 Expires Dec 23, 2027
US10617695 Expires Mar 19, 2027
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

FDA Approval: NDA022134 → Patents: FDA Orange Book → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.